US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

16.23

+0.75004.84%

Volume:308.07K

Turnover:4.78M

Market Cap:889.11M

PE:-7.29

High:16.31

Open:15.46

Low:15.13

Close:15.48

52wk High:19.71

52wk Low:7.80

Shares:54.78M

Float Shares:24.13M

Volume Ratio:1.16

T/O Rate:1.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.21

PE(LYR):-4.01

Loading ...

Overview Company News Filings

BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook

Bicara Therapeutics Inc - Anticipates Multiple Data Readouts in 2026 for Ficerafusp Alfa

THOMSON REUTERS

Bicara Therapeutics - Expects to Achieve Substantial Enrollment in Fortifi-Hn01 in 2026 to Enable Interim Analysis in Mid-2027

THOMSON REUTERS

Bicara Therapeutics Initiated at Buy by BTIG

Bicara Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $28

THOMSON REUTERS

BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target

MT Newswires Live

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares

How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story

Simply Wall St.

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment

MT Newswires Live

Bicara Therapeutics (BCAX): Assessing Valuation After Breakthrough Therapy Designation and Early Trial Data Progress

Simply Wall St.

Bicara Therapeutics Advances Ficerafusp Alfa to Pivotal Study Dose Selection for Head and Neck Cancer

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares

Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses

Simply Wall St.

Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":16.23,"timestamp":1771868701731,"preClose":15.48,"halted":0,"volume":308070,"delay":0,"changeRate":0.04844961240310077,"floatShares":24134001,"shares":54781950,"eps":-2.227112,"marketStatus":"Trading","change":0.75,"latestTime":"02-23 12:45:17 EST","open":15.46,"high":16.31,"low":15.125,"amount":4782467.28141,"amplitude":0.07655,"askPrice":16.3,"askSize":139,"bidPrice":16.17,"bidSize":24,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":15.48,"postHourTrading":{"tag":"盘后","latestPrice":15.4,"preClose":15.48,"latestTime":"18:21 EST","volume":16095,"amount":250422.96,"timestamp":1771629669030,"change":-0.08,"changeRate":-0.005168,"amplitude":0.02584},"volumeRatio":1.159908,"impliedVol":0.4676,"impliedVolPercentile":0.5418},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134001,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":1.159908,"shares":54781950,"dividePrice":0,"high":16.31,"amplitude":0.07655,"preClose":15.48,"low":15.125,"week52Low":7.8,"pbRate":"2.21","week52High":19.71,"institutionHeld":0,"latestPrice":16.23,"committee":-0.705521,"eps":-2.227112,"divideRate":0,"volume":308070,"delay":0,"ttmEps":-2.227112,"open":15.46,"prevYearClose":16.83,"prevWeekClose":15.48,"prevMonthClose":16.8,"prevQuarterClose":16.83,"fiveDayClose":14.21,"twentyDayClose":16.74,"sixtyDayClose":18.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2308,"buy":0.5385,"hold":0.2308,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1770872400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-02-20","current":-7.287465,"percent":0.724234,"low":-22.704836,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"high":-5.144536,"avg":-10.656245,"sd":4.728316,"marketCap":844737669},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669}],"updateTime":1771868717057},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602851055","title":"BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851055?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:02","pubTimestamp":1768222960,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate OutlookJan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PRO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2602510369","title":"Bicara Therapeutics Inc - Anticipates Multiple Data Readouts in 2026 for Ficerafusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510369?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2602510367","title":"Bicara Therapeutics - Expects to Achieve Substantial Enrollment in Fortifi-Hn01 in 2026 to Enable Interim Analysis in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510367?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2601605362","title":"Bicara Therapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2601605362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601605362?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:28","pubTimestamp":1767878880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 08:28 ET (13:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2601936901","title":"Bicara Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601936901?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:31","pubTimestamp":1767875497,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2601369141","title":"BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369141","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369141?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:18","pubTimestamp":1767874704,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of Buy and mean price target of $30.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2593448761","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448761","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448761?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:03","pubTimestamp":1766523784,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL7GY46w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAL","DOW","CLYM","APD","CE","ARDT","BSX","CF","AJG","BAC","HOUS","BBNX","CPT","AZO","AMAT","BIIB","BK4107","BCAX","CMI","BK4147","ACAD","CRL","BK4090","DAL","ACHC","ALB","LU0345769631.USD","BK4548","CLW","IE00B7SZLL34.SGD","DD","SGXZ57979304.SGD","ALL","BRO","SG9999001176.USD","AVTX","AMRZ","ASH","COUR","CTVA","LU0234570918.USD","CBT","DG","AXTA","BTSG","ACM","LU1989763690.USD","ALSN","CGNX","CL"],"gpt_icon":0},{"id":"2592307249","title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592307249","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592307249?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:52","pubTimestamp":1765921958,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbFfP3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2591672522","title":"How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672522","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591672522?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:36","pubTimestamp":1765845384,"startTime":"0","endTime":"0","summary":"Earlier this month, Bicara Therapeutics reported preliminary Phase 1b data showing that weekly 750 mg ficerafusp alfa plus pembrolizumab was generally well tolerated in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma, and the FDA granted the combination Breakthrough Therapy Designation in this setting.\nNew biomarker findings suggesting stronger TGF-β inhibition and immune activation at the 1,500 mg dose level add scientific weight to Bicara’s ongoing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2591649410","title":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649410","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649410?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  15, 2025  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205352/0/en/Bicara-Therapeutics-to-Present-at-the-J-P-Morgan-2026-Annual-Healthcare-Conference-on-Monday-January-12.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0795875169.SGD","LU1791710582.SGD","LU0971096721.USD","LU2089283258.USD","XLV","BK4516","BK4585","LU1732799900.SGD","BK4127","LU2111349929.HKD","LU0029874061.USD","BK4137","LU0795875086.SGD","LU0128526141.USD","LU0106831901.USD","LU1989772923.USD","LU1720051017.SGD","LU0314104364.USD","LU1791710400.SGD","LU1244550494.USD","BCAX","LU2133065610.SGD","LU1720051108.HKD","LU0098860793.USD","LABU","LU1244550221.USD","XBI","BK4504","LU2023251221.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","BK4581","LU0158827948.USD","LU0234570918.USD","LU0882574139.USD","HCSG","LU1363072403.SGD","LU1548497426.USD","LU1989772840.SGD","LU2089284900.SGD","LU0528227936.USD","LU1668664300.SGD","LU0267386448.USD","BK4588","IE00BKVL7J92.USD","LU2028103732.USD","LU1732800096.USD","LU2357305700.SGD","LU0006306889.USD"],"gpt_icon":0},{"id":"2589337903","title":"Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337903?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:57","pubTimestamp":1765195027,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was wel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2589508874","title":"Bicara Therapeutics (BCAX): Assessing Valuation After Breakthrough Therapy Designation and Early Trial Data Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2589508874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589508874?lang=en_us&edition=fundamental","pubTime":"2025-12-07 17:30","pubTimestamp":1765099831,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) just put a spotlight on its lead cancer program, pairing early Phase 1b data with an FDA Breakthrough Therapy designation, a one two punch that immediately sharpens the stock’s long term narrative.\nSee our latest analysis for Bicara Therapeutics.\nThe Breakthrough Therapy news arrives after a powerful run, with Bicara’s 1 month share price return of 24.32 percent and 3 month share price return of 48.09 percent. However, the 1 year total shareholder return is still...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-assessing-valuation-after-breakthro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-assessing-valuation-after-breakthro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4139","BK4097","BCAX","PRGS"],"gpt_icon":0},{"id":"2589825138","title":"Bicara Therapeutics Advances Ficerafusp Alfa to Pivotal Study Dose Selection for Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825138","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825138?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026022,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL6DMg1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","BCAX","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","SG9999014005.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2589825155","title":"Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825155","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825155?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026000,"startTime":"0","endTime":"0","summary":"Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201043/0/en/Bicara-Therapeutics-Preliminary-Phase-1b-Expansion-Cohort-Data-Evaluating-750mg-of-Ficerafusp-Alfa-Weekly-Plus-Pembrolizumab-Advances-Pivotal-Study-Dose-Selection-on-Track-for-Firs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPS","BK4124","BCAX"],"gpt_icon":0},{"id":"2588724750","title":"Bicara Therapeutics Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724750","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724750?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590456,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9hCKCp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BCAX","IE00BKPKM429.USD","BK4585","BK4588","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2586407221","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407221","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407221?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:42","pubTimestamp":1764114158,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL68hQYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2586407231","title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407231","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407231?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:40","pubTimestamp":1764114022,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL20y0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2586163744","title":"Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2586163744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586163744?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:14","pubTimestamp":1764026048,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) just released its earnings report for the third quarter and nine months through September 2025, revealing sharp changes in both net loss and basic loss per share compared to last year.\nSee our latest analysis for Bicara Therapeutics.\nThe latest share price surge, up 11.5% in a single day and 19.9% over the past week, signals renewed momentum for Bicara Therapeutics. However, with a total shareholder return of -1.2% over the past year, longer-term investors have not...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"1124620838","title":"Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1124620838","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124620838?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:24","pubTimestamp":1762874659,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) stock is soaring 5.03% in Tuesday's trading session, buoyed by a series of positive analyst ratings and increased price targets. The biotechnology company has caught the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}